No abstract available
Alzheimer's disease; casein kinase 2 (CK2) inhibitors; cilia; dopaminergic neurons; drug discovery; induced pluripotent stem cells (iPSCs); neuronal model; tau.
SGC, a registered charity (No. 1097737), receives funds from Bayer AG, Boehringer Ingelheim, the Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (a.k.a. EMD in Canada and USA); Pfizer; the São Paulo Research Foundation-FAPESP; and Takeda. This study was supported in part by NIH U24DK116204, NIH U54AG065187, and DoD ALSRP award AL190107.